Drug profile · INN
bardoxolone methyl
IMBARKYD
bardoxolone methyl (IMBARKYD) is a keap1/nrf2 inhibitor.
EMA: application withdrawn
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — bardoxolone methyl
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.83
Quick answer
bardoxolone methyl (IMBARKYD) is a keap1/nrf2 inhibitor.
Key facts
INN bardoxolone methyl
Brand IMBARKYD
Mechanism Keap1/Nrf2 inhibitor
Target Inhibitor of nuclear factor kappa-B kinase subunit beta
Mechanism of action
Keap1/Nrf2 inhibitor
Primary target: Inhibitor of nuclear factor kappa-B kinase subunit beta
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | application withdrawn | — |
Pipeline programs
Frequently asked questions
What is bardoxolone methyl?
bardoxolone methyl (IMBARKYD) is a keap1/nrf2 inhibitor.
What is the brand name for bardoxolone methyl?
IMBARKYD is a marketed brand name for bardoxolone methyl. Check FDA Drugs@FDA for the current US label holder and prescribing information.